<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38932420</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Determinants of Systemic SARS-CoV-2-Specific Antibody Responses to Infection and to Vaccination: A Secondary Analysis of Randomised Controlled Trial Data.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">691</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12060691</ELocationID><Abstract><AbstractText>SARS-CoV-2 infections elicit antibodies against the viral spike (S) and nucleocapsid (N) proteins; COVID-19 vaccines against the S-protein only. The BCG-Corona trial, initiated in March 2020 in SARS-CoV-2-na&#xef;ve Dutch healthcare workers, captured several epidemic peaks and the introduction of COVID-19 vaccines during the one-year follow-up. We assessed determinants of systemic anti-S1 and anti-N immunoglobulin type G (IgG) responses using trial data. Participants were randomised to BCG or placebo vaccination, reported daily symptoms, SARS-CoV-2 test results, and COVID-19 vaccinations, and donated blood for SARS-CoV-2 serology at two time points. In the 970 participants, anti-S1 geometric mean antibody concentrations (GMCs) were much higher than anti-N GMCs. Anti-S1 GMCs significantly increased with increasing number of immune events (SARS-CoV-2 infection or COVID-19 vaccination): 104.7 international units (IU)/mL, 955.0 IU/mL, and 2290.9 IU/mL for one, two, and three immune events, respectively (<i>p</i> &lt; 0.001). In adjusted multivariable linear regression models, anti-S1 and anti-N log<sub>10</sub> concentrations were significantly associated with infection severity, and anti-S1 log<sub>10</sub> concentration with COVID-19 vaccine type/dose. In univariable models, anti-N log<sub>10</sub> concentration was also significantly associated with acute infection duration, and severity and duration of individual symptoms. Antibody concentrations were not associated with long COVID or long-term loss of smell/taste.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Claus</LastName><ForeName>Juana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, 3584 CG Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten Doesschate</LastName><ForeName>Thijs</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, 3584 CG Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Jeroen Bosch Ziekenhuis, 5223 GZ Hertogenbosch, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taks</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debisarun</LastName><ForeName>Priya A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smits</LastName><ForeName>Gaby</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Institute of Public Health and the Environment, 3720 BA Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Binnendijk</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Institute of Public Health and the Environment, 3720 BA Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Klis</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Institute of Public Health and the Environment, 3720 BA Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhagen</LastName><ForeName>Lilly M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Paediatric Infectious Diseases and Immunology, Amalia Children's Hospital, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jonge</LastName><ForeName>Marien I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonten</LastName><ForeName>Marc J M</ForeName><Initials>MJM</Initials><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, 3584 CG Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Netea</LastName><ForeName>Mihai G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Genomics &amp; Immunoregulation, Life and Medical Sciences Institute, University of Bonn, 53113 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Wijgert</LastName><ForeName>Janneke H H M</ForeName><Initials>JHHM</Initials><Identifier Source="ORCID">0000-0003-2728-4560</Identifier><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, 3584 CG Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>10430 01 201 0026</GrantID><Agency>Netherlands Organisation for Health Research and Development</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BCG</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">serology</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>L.M.V. reports consulting fees from MSD in the last 36 months (unrelated to the work in this manuscript, payments to institution). M.J.M.B. reports research grants from Janssen Vaccines, Novartis, CureVac, and Merck, Advisory Board memberships of Spherecydes, Pfizer, MSD, Novartis and AstraZeneca, and DSMB membership of Sanofi, in the last 36 months (unrelated to the work in this manuscript, payments to institution). M.G.N. is scientific founder and a scientific advisory board member of Trained Therapeutix Discovery (TTxD) and scientific founder of Lemba Therapeutics, has obtained research grants from GSK Biologicals, TTxD, and Ono Pharma, and consultancy fees from TTxD. J.H.H.M.v.d.W. reports payments for meeting attendance from the Dutch Ministry of Health and Sports and The Netherlands Organization for Health Research and Development (ZonMw) in the last 36 months (unrelated to the work in this manuscript, payments to institution). All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38932420</ArticleId><ArticleId IdType="pmc">PMC11209274</ArticleId><ArticleId IdType="doi">10.3390/vaccines12060691</ArticleId><ArticleId IdType="pii">vaccines12060691</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Munitz A., Edry-Botzer L., Itan M., Tur-Kaspa R., Dicker D., Marcoviciu D., Goren M.G., Mor M., Lev S., Gottesman T., et al. Rapid Seroconversion and Persistent Functional IgG Antibodies in Severe COVID-19 Patients Correlates with an IL-12p70 and IL-33 Signature. Sci. Rep. 2021;11:3461. doi: 10.1038/s41598-021-83019-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-83019-0</ArticleId><ArticleId IdType="pmc">PMC7876035</ArticleId><ArticleId IdType="pubmed">33568715</ArticleId></ArticleIdList></Reference><Reference><Citation>McAndrews K.M., Dowlatshahi D.P., Dai J., Becker L.M., Hensel J., Snowden L.M., Leveille J.M., Brunner M.R., Holden K.W., Hopkins N.S., et al. Heterogeneous Antibodies against SARS-CoV-2 Spike Receptor Binding Domain and Nucleocapsid with Implications for COVID-19 Immunity. JCI Insight. 2020;5:e142386. doi: 10.1172/jci.insight.142386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.142386</ArticleId><ArticleId IdType="pmc">PMC7526535</ArticleId><ArticleId IdType="pubmed">32796155</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Rao Z. Structural Biology of SARS-CoV-2 and Implications for Therapeutic Development. Nat. Rev. Microbiol. 2021;19:685&#x2013;700. doi: 10.1038/s41579-021-00630-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00630-8</ArticleId><ArticleId IdType="pmc">PMC8447893</ArticleId><ArticleId IdType="pubmed">34535791</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow J., Graham C., Merrick B., Acors S., Pickering S., Steel K.J.A., Hemmings O., O&#x2019;Bryne A., Kouphou N., Galao R.P., et al. Longitudinal Evaluation and Decline of Antibody Responses in SARS-CoV-2 Infection. Nat. Microbiol. 2020;5:1598&#x2013;1607. doi: 10.1038/s41564-020-00813-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00813-8</ArticleId><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh E.E., Frenck R.W., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439&#x2013;2450. doi: 10.1056/NEJMoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., C&#xe1;rdenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 2021;384:2187&#x2013;2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett J.R., Belij-Rammerstorfer S., Dold C., Ewer K.J., Folegatti P.M., Gilbride C., Halkerston R., Hill J., Jenkin D., Stockdale L., et al. Phase 1/2 Trial of SARS-CoV-2 Vaccine ChAdOx1 nCoV-19 with a Booster Dose Induces Multifunctional Antibody Responses. Nat. Med. 2021;27:279&#x2013;288. doi: 10.1038/s41591-020-01179-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01179-4</ArticleId><ArticleId IdType="pubmed">33335322</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternberg A., Naujokat C. Structural Features of Coronavirus SARS-CoV-2 Spike Protein: Targets for Vaccination. Life Sci. 2020;257:118056. doi: 10.1016/j.lfs.2020.118056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118056</ArticleId><ArticleId IdType="pmc">PMC7336130</ArticleId><ArticleId IdType="pubmed">32645344</ArticleId></ArticleIdList></Reference><Reference><Citation>Solastie A., Virta C., Haveri A., Ekstr&#xf6;m N., Kantele A., Miettinen S., Lempainen J., Jalkanen P., Kakkola L., Dub T., et al. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies. Microbiol. Spectr. 2021;9:e01131-21. doi: 10.1128/Spectrum.01131-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01131-21</ArticleId><ArticleId IdType="pmc">PMC8597651</ArticleId><ArticleId IdType="pubmed">34787485</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontou P.I., Braliou G.G., Dimou N.L., Nikolopoulos G., Bagos P.G. Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. Diagnostics. 2020;10:319. doi: 10.3390/diagnostics10050319.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics10050319</ArticleId><ArticleId IdType="pmc">PMC7278002</ArticleId><ArticleId IdType="pubmed">32438677</ArticleId></ArticleIdList></Reference><Reference><Citation>den Hartog G., Schepp R.M., Kuijer M., GeurtsvanKessel C., van Beek J., Rots N., Koopmans M.P.G., van der Klis F.R.M., van Binnendijk R.S. SARS-CoV-2&#x2013;Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. J. Infect. Dis. 2020;222:1452&#x2013;1461. doi: 10.1093/infdis/jiaa479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa479</ArticleId><ArticleId IdType="pmc">PMC7454740</ArticleId><ArticleId IdType="pubmed">32766833</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen L.L., Smits G., van Hagen C.C.E., Wong D., Vos E.R.A., van Boven M., de Melker H.E., van Vliet J., Kuijer M., Woudstra L., et al. Seropositivity to Nucleoprotein to Detect Mild and Asymptomatic SARS-CoV-2 Infections: A Complementary Tool to Detect Breakthrough Infections after COVID-19 Vaccination? Vaccine. 2022;40:2251&#x2013;2257. doi: 10.1016/j.vaccine.2022.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.009</ArticleId><ArticleId IdType="pmc">PMC8904156</ArticleId><ArticleId IdType="pubmed">35287986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilocca B., Soggiu A., Sanguinetti M., Musella V., Britti D., Bonizzi L., Urbani A., Roncada P. Comparative Computational Analysis of SARS-CoV-2 Nucleocapsid Protein Epitopes in Taxonomically Related Coronaviruses. Microbes Infect. 2020;22:188&#x2013;194. doi: 10.1016/j.micinf.2020.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2020.04.002</ArticleId><ArticleId IdType="pmc">PMC7156246</ArticleId><ArticleId IdType="pubmed">32302675</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.-J., Goh P.-Y., Fielding B.C., Shen S., Chou C.-F., Fu J.-L., Leong H.N., Leo Y.S., Ooi E.E., Ling A.E., et al. Profiles of Antibody Responses against Severe Acute Respiratory Syndrome Coronavirus Recombinant Proteins and Their Potential Use as Diagnostic Markers. Clin. Diagn. Lab. Immunol. 2004;11:362&#x2013;371. doi: 10.1128/cdli.11.2.362-371.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cdli.11.2.362-371.2004</ArticleId><ArticleId IdType="pmc">PMC371215</ArticleId><ArticleId IdType="pubmed">15013989</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C., Nilsson J., Zurbuchen Y., Valaperti A., Schreiner J., Wolfensberger A., Raeber M.E., Adamo S., Weigang S., Emmenegger M., et al. Systemic and Mucosal Antibody Responses Specific to SARS-CoV-2 during Mild versus Severe COVID-19. J. Allergy Clin. Immunol. 2021;147:545&#x2013;557.e9. doi: 10.1016/j.jaci.2020.10.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.10.040</ArticleId><ArticleId IdType="pmc">PMC7677074</ArticleId><ArticleId IdType="pubmed">33221383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou B., Li T.-D., Zheng S.-F., Su Y.-Y., Li Z.-Y., Liu W., Yu F., Ge S.-X., Zou Q.-D., Yuan Q., et al. Serology Characteristics of SARS-CoV-2 Infection since Exposure and Post Symptom Onset. Eur. Respir. J. 2020;56:2000763. doi: 10.1183/13993003.00763-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00763-2020</ArticleId><ArticleId IdType="pmc">PMC7401320</ArticleId><ArticleId IdType="pubmed">32430429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zervou F.N., Louie P., Stachel A., Zacharioudakis I.M., Ortiz-Mendez Y., Thomas K., Aguero-Rosenfeld M.E. SARS-CoV-2 Antibodies: IgA Correlates with Severity of Disease in Early COVID-19 Infection. J. Med. Virol. 2021;93:5409&#x2013;5415. doi: 10.1002/jmv.27058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27058</ArticleId><ArticleId IdType="pmc">PMC8242647</ArticleId><ArticleId IdType="pubmed">33932299</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf6;lfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., M&#xfc;ller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C., et al. Virological Assessment of Hospitalized Patients with COVID-2019. Nature. 2020;581:465&#x2013;469. doi: 10.1038/s41586-020-2196-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection A Minimal Common Outcome Measure Set for COVID-19 Clinical Research. Lancet Infect. Dis. 2020;20:e192&#x2013;e197. doi: 10.1016/S1473-3099(20)30483-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Claus J., ten Doesschate T., Gumbs C., van Werkhoven C.H., van der Vaart T.W., Janssen A.B., Smits G., van Binnendijk R., van der Klis F., van Baarle D., et al. BCG Vaccination of Health Care Workers Does Not Reduce SARS-CoV-2 Infections nor Infection Severity or Duration: A Randomized Placebo-Controlled Trial. mBio. 2023;14:e00356-23. doi: 10.1128/mbio.00356-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00356-23</ArticleId><ArticleId IdType="pmc">PMC10128007</ArticleId><ArticleId IdType="pubmed">36976004</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . First WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin (Human) World Health Organization; Geneva, Switzerland: 2020.</Citation></Reference><Reference><Citation>Vos E.R.A., van Boven M., den Hartog G., Backer J.A., Klinkenberg D., van Hagen C.C.E., Boshuizen H., van Binnendijk R.S., Mollema L., van der Klis F.R.M., et al. Associations between Measures of Social Distancing and Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity: A Nationwide Population-Based Study in the Netherlands. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021;73:2318&#x2013;2321. doi: 10.1093/cid/ciab264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab264</ArticleId><ArticleId IdType="pmc">PMC8083720</ArticleId><ArticleId IdType="pubmed">33772265</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen L.L., Verheul M.K., Vos E.R.A., van Hagen C.C.E., van Boven M., Wong D., Wijmenga-Monsuur A.J., Smits G., Kuijer M., van Rooijen D., et al. SARS-CoV-2 Spike S1-Specific IgG Kinetic Profiles Following mRNA or Vector-Based Vaccination in the General Dutch Population Show Distinct Kinetics. Sci. Rep. 2022;12:5935. doi: 10.1038/s41598-022-10020-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-10020-6</ArticleId><ArticleId IdType="pmc">PMC8990276</ArticleId><ArticleId IdType="pubmed">35396570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Stoesser N., Matthews P.C., Ayoubkhani D., Studley R., Bell I., Bell J.I., Newton J.N., Farrar J., Diamond I., et al. Antibody Responses to SARS-CoV-2 Vaccines in 45,965 Adults from the General Population of the United Kingdom. Nat. Microbiol. 2021;6:1140&#x2013;1149. doi: 10.1038/s41564-021-00947-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00947-3</ArticleId><ArticleId IdType="pmc">PMC8294260</ArticleId><ArticleId IdType="pubmed">34290390</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyre D.W., Lumley S.F., Wei J., Cox S., James T., Justice A., Jesuthasan G., O&#x2019;Donnell D., Howarth A., Hatch S.B., et al. Quantitative SARS-CoV-2 Anti-Spike Responses to Pfizer&#x2013;BioNTech and Oxford&#x2013;AstraZeneca Vaccines by Previous Infection Status. Clin. Microbiol. Infect. 2021;27:1516.e7&#x2013;1516.e14. doi: 10.1016/j.cmi.2021.05.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.041</ArticleId><ArticleId IdType="pmc">PMC8180449</ArticleId><ArticleId IdType="pubmed">34111577</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooley N., Abdool Karim S.S., Combadi&#xe8;re B., Ooi E.E., Harris R.C., El Guerche Seblain C., Kisomi M., Shaikh N. Durability of Vaccine-Induced and Natural Immunity against COVID-19: A Narrative Review. Infect. Dis. Ther. 2023;12:367&#x2013;387. doi: 10.1007/s40121-022-00753-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00753-2</ArticleId><ArticleId IdType="pmc">PMC9828372</ArticleId><ArticleId IdType="pubmed">36622633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V., Foulkes S., Insalata F., Kirwan P., Saei A., Atti A., Wellington E., Khawam J., Munro K., Cole M., et al. Protection against SARS-CoV-2 after COVID-19 Vaccination and Previous Infection. N. Engl. J. Med. 2022;386:1207&#x2013;1220. doi: 10.1056/NEJMoa2118691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118691</ArticleId><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N., Ware H., Ma X., Li Z., Hosseini R., Cao C., Selemon A., Whelan M., Premji Z., Issa H., et al. Protective Effectiveness of Previous SARS-CoV-2 Infection and Hybrid Immunity against the Omicron Variant and Severe Disease: A Systematic Review and Meta-Regression. Lancet Infect. Dis. 2023;23:556&#x2013;567. doi: 10.1016/S1473-3099(22)00801-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Legros V., Denolly S., Vogrig M., Boson B., Siret E., Rigaill J., Pillet S., Grattard F., Gonzalo S., Verhoeven P., et al. A Longitudinal Study of SARS-CoV-2-Infected Patients Reveals a High Correlation between Neutralizing Antibodies and COVID-19 Severity. Cell. Mol. Immunol. 2021;18:318&#x2013;327. doi: 10.1038/s41423-020-00588-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00588-2</ArticleId><ArticleId IdType="pmc">PMC7786875</ArticleId><ArticleId IdType="pubmed">33408342</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrotri M., Navaratnam A.M.D., Nguyen V., Byrne T., Geismar C., Fragaszy E., Beale S., Fong W.L.E., Patel P., Kovar J., et al. Spike-Antibody Waning after Second Dose of BNT162b2 or ChAdOx1. Lancet. 2021;398:385&#x2013;387. doi: 10.1016/S0140-6736(21)01642-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01642-1</ArticleId><ArticleId IdType="pmc">PMC8285117</ArticleId><ArticleId IdType="pubmed">34274038</ArticleId></ArticleIdList></Reference><Reference><Citation>Koekenbier E.L., Fohse K., van de Maat J.S., Oosterheert J.J., van Nieuwkoop C., Hoogerwerf J.J., Grobusch M.P., van den Bosch M.A.A.J., van de Wijgert J.H.H., Netea M.G., et al. Bacillus Calmette-Gu&#xe9;rin Vaccine for Prevention of COVID-19 and Other Respiratory Tract Infections in Older Adults with Comorbidities: A Randomized Controlled Trial. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2023;29:781&#x2013;788. doi: 10.1016/j.cmi.2023.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.01.019</ArticleId><ArticleId IdType="pmc">PMC9892323</ArticleId><ArticleId IdType="pubmed">36736662</ArticleId></ArticleIdList></Reference><Reference><Citation>Moorlag S.J.C.F.M., Taks E., Ten Doesschate T., van der Vaart T.W., Janssen A.B., M&#xfc;ller L., Ostermann P., Dijkstra H., Lemmers H., Simonetti E., et al. Efficacy of BCG Vaccination against Respiratory Tract Infections in Older Adults during the Coronavirus Disease 2019 Pandemic. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2022;75:e938&#x2013;e946. doi: 10.1093/cid/ciac182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac182</ArticleId><ArticleId IdType="pmc">PMC8903481</ArticleId><ArticleId IdType="pubmed">35247264</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil H.P., Rane P.S., Shrivastava S., Palkar S., Lalwani S., Mishra A.C., Arankalle V.A. Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients. Viral Immunol. 2021;34:201&#x2013;209. doi: 10.1089/vim.2020.0321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2020.0321</ArticleId><ArticleId IdType="pubmed">33656935</ArticleId></ArticleIdList></Reference><Reference><Citation>To K.K.-W., Tsang O.T.-Y., Leung W.-S., Tam A.R., Wu T.-C., Lung D.C., Yip C.C.-Y., Cai J.-P., Chan J.M.-C., Chik T.S.-H., et al. Temporal Profiles of Viral Load in Posterior Oropharyngeal Saliva Samples and Serum Antibody Responses during Infection by SARS-CoV-2: An Observational Cohort Study. Lancet Infect. Dis. 2020;20:565&#x2013;574. doi: 10.1016/S1473-3099(20)30196-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30196-1</ArticleId><ArticleId IdType="pmc">PMC7158907</ArticleId><ArticleId IdType="pubmed">32213337</ArticleId></ArticleIdList></Reference><Reference><Citation>Takita M., Yoshida T., Tsuchida T., Nakagama Y., Kido Y., Suzuki S., Imamura M., Kawahata K., Shimizu G., Yoshida H., et al. Low SARS-CoV-2 Antibody Titers May Be Associated with Poor Clinical Outcomes for Patients with Severe COVID-19. Sci. Rep. 2022;12:9147. doi: 10.1038/s41598-022-12834-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-12834-w</ArticleId><ArticleId IdType="pmc">PMC9159042</ArticleId><ArticleId IdType="pubmed">35650227</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J., Padilla S., Fern&#xe1;ndez-Gonz&#xe1;lez M., Garc&#xed;a J.A., Agull&#xf3; V., Andreo M., Ruiz S., Galiana A., Guti&#xe9;rrez F., Masi&#xe1; M. Antibody Response to SARS-CoV-2 Is Associated with Long-Term Clinical Outcome in Patients with COVID-19: A Longitudinal Study. J. Clin. Immunol. 2021;41:1490&#x2013;1501. doi: 10.1007/s10875-021-01083-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C., Zurbuchen Y., Taeschler P., Ballouz T., Menges D., Hasler S., Adamo S., Raeber M.E., B&#xe4;chli E., Rudiger A., et al. Immunoglobulin Signature Predicts Risk of Post-Acute COVID-19 Syndrome. Nat. Commun. 2022;13:446. doi: 10.1038/s41467-021-27797-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M., Schommers P., Stecher M., Dewald F., Gieselmann L., Gruell H., Horn C., Vanshylla K., Cristanziano V.D., Osebold L., et al. Post-COVID Syndrome in Non-Hospitalised Patients with COVID-19: A Longitudinal Prospective Cohort Study. Lancet Reg. Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Joung S., Weber B., Wu M., Liu Y., Tang A.B., Driver M., Sternbach S., Wynter T., Hoang A., Barajas D., et al. Serological Response to Vaccination in Post-Acute Sequelae of COVID. BMC Infect. Dis. 2023;23:97. doi: 10.1186/s12879-023-08060-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08060-y</ArticleId><ArticleId IdType="pmc">PMC9933819</ArticleId><ArticleId IdType="pubmed">36797666</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Yuan Q., Wang H., Liu W., Liao X., Su Y., Wang X., Yuan J., Li T., Li J., et al. Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease 2019. Clin. Infect. Dis. 2020;71:2027&#x2013;2034. doi: 10.1093/cid/ciaa344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa344</ArticleId><ArticleId IdType="pmc">PMC7184337</ArticleId><ArticleId IdType="pubmed">32221519</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q.-X., Liu B.-Z., Deng H.-J., Wu G.-C., Deng K., Chen Y.-K., Liao P., Qiu J.-F., Lin Y., Cai X.-F., et al. Antibody Responses to SARS-CoV-2 in Patients with COVID-19. Nat. Med. 2020;26:845&#x2013;848. doi: 10.1038/s41591-020-0897-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0897-1</ArticleId><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A Clinical Case Definition of Post-COVID-19 Condition by a Delphi Consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xda;ri K., Fagyas M., Kert&#xe9;sz A., Borb&#xe9;ly A., Jenei C., Bene O., Csan&#xe1;di Z., Paulus W.J., &#xc9;des I., Papp Z., et al. Circulating ACE2 Activity Correlates with Cardiovascular Disease Development. J. Renin-Angiotensin-Aldosterone Syst. JRAAS. 2016;17:1470320316668435. doi: 10.1177/1470320316668435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1470320316668435</ArticleId><ArticleId IdType="pmc">PMC5843890</ArticleId><ArticleId IdType="pubmed">27965422</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.C., Zhang J., Zhuo J.L. The Vasoprotective Axes of the Renin-Angiotensin System: Physiological Relevance and Therapeutic Implications in Cardiovascular, Hypertensive and Kidney Diseases. Pharmacol. Res. 2017;125:21&#x2013;38. doi: 10.1016/j.phrs.2017.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2017.06.005</ArticleId><ArticleId IdType="pmc">PMC5607101</ArticleId><ArticleId IdType="pubmed">28619367</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>